Abstract 2121P
Background
Recently, the development of anticancer drug administration methods and advances in supportive care for side effects have made it possible to safely perform chemotherapy through outpatient visits. Outpatient chemotherapy is important for maintaining the patient's quality of life (QOL). Side effects of chemotherapy include anorexia, nausea, dysgeusia, and oral mucosal disorders, which affect diet, and weight loss affecting the effectiveness and prognosis. In particular, patients with gastrointestinal cancer are considered to have a high nutritional risk status. We assessed the nutritional status of patients with gastrointestinal cancer during outpatient chemotherapy and found an association with adverse events symptoms.
Methods
The Tohoku University School of Medicine IRB approved this study (2018-1-176); patients provided written informed consent. Patients undergoing outpatient chemotherapy were enrolled, nutritional status, self-assessment of adverse events and depression by The Depression Scale Epidemiological Research Center (CES-D) were assessed. Responses were analyzed by Chi-squared test, ANOVA, Spearman's correlation coefficient, and multiple regression analysis. p<0.05 was considered significant. All statistical analyses were performed using SPSS (ver. 21).
Results
Valid responses were obtained from 120 patients with gastrointestinal cancers including pancreatic, colorectal, gastric, and esophageal cancers. The mean age was 65.2 (±9.6) years. Side effects of chemotherapy were fatigue in 99 (83.9%), neuropathy in 88 (73.3%), and dysgeusia in 85 (70.8%). Subjects were classified into 70 normal persons, 32 malnourished, 6 pre-cachexia, and 12 cachexia according to the nutrition assessment classification by Glasgow prognostic score (GPS). Although GPS classification did not show a significant relationship with the basic attributes, there was a significant relationship between anorexia (r=0.26, p=0.004), taste change (r=0.26, p=0.005), dry mouth (r=0.18, p=0.049), and edema (r=0.22, p=0.018).
Conclusions
Adverse events during chemotherapy including anorexia, dysgeusia, dry mouth and edema would have negative impact on nutritional status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
JSPS KAKENHI Grant Number JP 16K07140.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06